Action LightWave Acquisition - LWAC

LightWave Acquisition Corporation (LWAC) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

10,20

( - )

Prix Achat

3,91

Prix Vente

10,27

Volume échangé

10,25 Fourchette du Jour 10,25

9,94 Plage de 52 semaines 16,98

Cap du marché

306,765M

Clôture Veille

10,20

Ouverture

10,25

Dernière Transaction

10.25

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

US$ 13 067

Actions en circulation

30 075 000

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

Bénéfice par action (BPA)

Chiffre d'affairess (LTM)

Bénéfice net (LTM)

3,96M

LightWave Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. LightWave Acquisition Corp. was incorporated in 20... LightWave Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. LightWave Acquisition Corp. was incorporated in 2025 and is based in Dallas, Texas. Show more

Secteur

Industrie

Site Web

lightwaveacquisition.com

Siège social

Dallas, United States

Fondé

2026

LightWave Acquisition Corporation est coté dans le secteur de la NASDAQ avec le ticker LWAC. Le dernier cours de clôture d'LightWave Acquisition était de US$10,20. Au cours de la dernière année, les actions de LightWave Acquisition ont été négociées dans une fourchette de prix de US$ 9,94 à US$ 16,98.

LightWave Acquisition compte actuellement 30 075 000 actions en circulation. La capitalisation boursière d'LightWave Acquisition est de US$306,77 million.

LightWave Acquisition Corp. Announces Closing of $215,625,000 Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option

Dallas, TX, June 26, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the “Company”), a newly organized special purpose acquisition...

LightWave Acquisition Corp. Announces Pricing of $187,500,000 Initial Public Offering

Dallas, TX, June 24, 2025 (GLOBE NEWSWIRE) -- LightWave Acquisition Corp. (the “Company”), a newly organized special purpose acquisition...

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the...

Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ: LWAC) (“LWAC” or the “Company”), a special purpose...

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of...

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of...

Locust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report ...

BOSTON, June 03, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ: LWAC) (the “Company”), a blank-check company formed for the...

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation ...

Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	10.2	10.25	10.2	5876	10.2000434	CS
4	-0.0099	-0.0969647107219	10.2099	10.29	10.2	6859	10.20059852	CS
12	0	0	10.2	10.29	10.155	7010	10.18376975	CS
26	0.17	1.69491525424	10.03	10.29	10.03	25981	10.1042143	CS
52	-6.78	-39.9293286219	16.98	16.98	9.94	33173	10.04667111	CS
156	-6.78	-39.9293286219	16.98	16.98	9.94	11043	10.04667111	CS
260	0.31	3.13447927199	9.89	29.2	8.33	18100	12.39637303	CS

LWAC - Frequently Asked Questions (FAQ)

What is the current LightWave Acquisition Corporation share price?

The current share price of LightWave Acquisition Corporation is US$ 10,20

How many LightWave Acquisition Corporation shares are in issue?

LightWave Acquisition Corporation has 30 075 000 shares in issue

What is the market cap of LightWave Acquisition Corporation?

The market capitalisation of LightWave Acquisition Corporation is USD 306,77M

What is the 1 year trading range for LightWave Acquisition Corporation share price?

LightWave Acquisition Corporation has traded in the range of US$ 9,94 to US$ 16,98 during the past year

What is the registered address of LightWave Acquisition Corporation?

The registered address for LightWave Acquisition Corporation is 14755 Preston Road, Dallas, Texas, 75254

What is the LightWave Acquisition Corporation website address?

The website address for LightWave Acquisition Corporation is lightwaveacquisition.com

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

LightWave Acquisition Corporation (LWAC)

LightWave Acquisition Corporation (LWAC) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de LightWave Acquisition Corporation

LWAC Dernières nouvelles

LightWave Acquisition Corp. Announces Closing of $215,625,000 Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option

LightWave Acquisition Corp. Announces Pricing of $187,500,000 Initial Public Offering

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

Locust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report ...

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation ...

LWAC - Frequently Asked Questions (FAQ)

LWAC Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

LightWave Acquisition Corporation (LWAC)

LightWave Acquisition Corporation (LWAC) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de LightWave Acquisition Corporation

LWAC Dernières nouvelles

LightWave Acquisition Corp. Announces Closing of $215,625,000 Initial Public Offering, Including Full Exercise of Underwriters' Over-Allotment Option

LightWave Acquisition Corp. Announces Pricing of $187,500,000 Initial Public Offering

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies

Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports

Locust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report ...

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation ...

LWAC - Frequently Asked Questions (FAQ)

LWAC Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Inscrivez-vous GRATUITEMENT et obtenez:

Supprimer les publicités